total revenu y/i fx well ahead
street estim organ growth robust vs estimate
beat broad-bas end-market geographi product categori gross
opmargin declin yoy expect due pthn deal opm
ahead est adj ep street beat larg
expect given market trend better even bullish expect
underscor tmo strong fundament first look page note
detail end-market geographi guidanc
beat roll growth keep acceler
rais organ sale guid adj ep
mdpt vs prior said view updat guid still somewhat
conserv upsid go given tmo key end-market appear
boom unison market environ strength tmo diversifi
global busi amplifi believ share well-posit
narrow pe valuat gap lst peer also emphas throughout
call busi continu thrive china organ sale growth
despit persist concern tariff/trad war neg impact still
expect neglig revenu ep
also clearli win share vs competit sever key market particularli pharma
bode well continu improv organ growth profil reiter
buy rate share see divers underappreci strength
rais estim see organ out-year
estimate sale y/i organ fx vs
prior adj ep y/i sale
organ vs prior adj ep yoy vs prior
po dcf base w/ wacc due higher impli market return
termin growth rate improv metric unchang
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
thermo fisher scientif largest
consist analyt instrument lab
equip consum softwar servic
use throughout research drug manufactur
diagnost food consum product safeti
environment test
thermo fisher scientif largest life scienc
tool compani think recent acquisit
complementari technolog higher growth
on-going process improv initi
expand footprint emerg appli
market help grow revenu steadili
line even modestli better
overal tool market deliv low teen ep
compound-annual-growth-rate next sever year
life scienc solut sale segment sale
y/i organ fx vs estim y/i
organ fx saw good growth across busi
segment clinic next-gen sequenc bio-product bioscienc genet
scienc opm yoy strong product volum
pull-through favor fx partial off-set strateg invest
analyt instrument sale analyt instrument revenu
y/i organ fx vs estim
y/i organ fx growth broad-bas
well even strength across chemic analysi chromatographi mass
spectrometri electron microscopi opm strong
product volum pull-through partial off-set strateg invest
specialti diagnost sale specialti diagnost revenu
y/i organ fx vs estim
y/i organ fx management report strong growth
transplant diagnost clinic diagnost busi well
health care market channel opm flat yoy volum leverag
favor fx off-set strateg invest busi mix
laboratori product servic lp sale laboratori product
servic lp revenu y/i organ fx
 vs estim y/i organ fx
 growth broad-bas led clinic trial logist busi
research safeti market channel opm yoy
slightli accret pthn good volum leverag off-set
busi mix strateg invest
academ govern revenu grew high-singl digit y/i solid
result geographi increas flow fund us
diagnost healthcar sale grew mid-singl digit
industri appli growth end-market mid-singl digit
driven continu strong demand analyt instrument
pharma sale grew mid-teen yoy management note broad
strength well share gain chromatographi mass spec like
compet clinic trial logist busi
north america sale msd
europ sale hsd
asia pacif sale low-teen includ anoth stellar quarter
china
rest world sale low-teen
revenu rais sale guid
mdpt midpoint equat report growth
organ growth guid rais vs prior
year includ beat
increment acquisit stronger patheon perform
yet includ contribut gatan link
increment lower fx tailwind total
margin expect oper margin expans y/i
inclus margin dilut pthn acquisit
interest expens manag expect full year net interest expens
result pthn acquisit slight reduct prior guid
tax rate manag expect adjust tax rate
level result recent pass us tax reform unchang
capit deploy share buyback inclus complet
start point later year
also plan total dividend payment year usual
compani note capit deploy embed
current guidanc excess cash use repay debt unchang
share count manag estim averag dilut share
vs due equiti offer financ pthn deal
unchang
capit expenditur manag expect net capit expenditur
approxim elev due time project
full-year impact patheon receiv approxim custom
fund toward capital-expenditure free cash flow expect
ep non-gaap ep rais prior
oper perform
increment softer fx total fx
expect tariff impact lower interest expens
po base dcf model assum wacc termin
growth rate impli multipl approxim ep estim in-lin
compani peer group averag given size market leadership matur
stabil compani consum focus busi believ dcf
appropri way valu compani risk price object deal
integr risk lower-than-expect deal synergi slower growth emerg
market price eros lower healthcar util trend soft uptak new
product competit weak fund
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
